Bristol-Myers Squibb Company stock (US0897961004): EU approval for Sotyktu in psoriatic arthritis lifts sentiment

Bristol-Myers Squibb won European Commission approval for Sotyktu in active psoriatic arthritis, expanding the drug’s reach and supporting the company’s immunology pipeline.

Bristol-Myers Squibb Company stock (NYSE: BMY) is drawing fresh attention after the European Commission granted approval for Sotyktu (deucravacitinib) for the treatment of active psoriatic arthritis in adults, a move that broadens the drug’s label beyond plaque psoriasis and underpins the company’s immunology growth story. The decision, announced on May 8, 2026, allows Sotyktu to be used alone or in combination with methotrexate in patients who have had an inadequate response or intolerance to prior disease?modifying antirheumatic therapy, according to a corporate press release from Bristol Myers Squibb.Bristol Myers Squibb press release as of 05/08/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb Company
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Princeton, New Jersey, United States
• Core markets: United States, Europe, Japan and other developed markets
• Key revenue drivers: Oncology, immunology, cardiovascular and hematology products
• Home exchange/listing venue: New York Stock Exchange (ticker: BMY)
• Trading currency: US dollar

Bristol-Myers Squibb Company: core business model

Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing and commercializing innovative medicines for serious diseases, including cancer, autoimmune disorders, cardiovascular conditions and blood disorders. The company operates across multiple therapeutic areas and relies on a portfolio of branded prescription drugs, many of which are protected by patents and benefit from strong pricing power in key markets such as the United States and Europe.Bristol Myers Squibb corporate site as of 05/09/2026

The company’s business model centers on high?margin specialty medicines, supported by research and development investments, strategic partnerships and in?licensing deals that expand its pipeline. Bristol Myers Squibb also leverages large?scale commercial infrastructure to market its products to physicians, hospitals and payers, while managing regulatory and reimbursement dynamics in major healthcare systems. This focus on innovative therapies positions the firm as a core holding for many US investors seeking exposure to the global pharmaceutical sector.Bristol Myers Squibb corporate site as of 05/09/2026

Main revenue and product drivers for Bristol-Myers Squibb Company

Oncology remains the largest revenue driver for Bristol-Myers Squibb, with products such as Opdivo (nivolumab) and other immuno?oncology agents contributing a substantial share of sales. The company also generates meaningful income from immunology assets, including Sotyktu, which was first approved for moderate?to?severe plaque psoriasis and is now gaining traction in psoriatic arthritis, a chronic inflammatory joint condition that affects millions of patients worldwide.Bristol Myers Squibb press release as of 05/08/2026

Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action that modulates key cytokines involved in plaque psoriasis and psoriatic arthritis. In the pivotal Phase 3 POETYK PsA trials, Sotyktu showed superiority versus placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality?of?life measures reflected in the European Union Summary of Product Characteristics.Bristol Myers Squibb press release as of 05/08/2026

For US investors, the EU approval of Sotyktu in psoriatic arthritis is relevant because it signals incremental commercial upside in a large, established market and may support future pricing and reimbursement discussions in the United States. The decision also reinforces Bristol Myers Squibb’s strategy of extending the lifecycle of key assets through label expansions, which can help offset patent expirations and competitive pressures in other parts of the portfolio.Bristol Myers Squibb press release as of 05/08/2026

Conclusion

Bristol-Myers Squibb Company’s latest EU approval for Sotyktu in active psoriatic arthritis adds a new indication to a growing immunology franchise and may contribute to future revenue growth, particularly in Europe and potentially in the United States. The decision reflects the company’s continued focus on innovative, targeted therapies and its ability to expand indications for existing assets, which can help sustain margins and support long?term shareholder value.Bristol Myers Squibb press release as of 05/08/2026

For US investors, Bristol-Myers Squibb Company offers exposure to a diversified pharmaceutical portfolio with established oncology brands and an expanding immunology pipeline, but the stock also faces risks from patent expirations, pricing pressures and regulatory scrutiny. The Sotyktu approval is a positive catalyst, yet it should be weighed alongside broader sector dynamics and the company’s overall growth and profitability profile.Bristol Myers Squibb corporate site as of 05/09/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.